Resources Archive - Page 25 of 48

Emerging Drug Discovery Strategies for Targeted Protein Degradation

In the last decade, targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific...

Leveraging Animal Models to Combat Drug Resistance in Cancer Therapy

Cancer, globally recognized as a significant threat to public health, can be effectively controlled in its early stages through chemotherapy, targeted...

TAAR1 as an Emerging Target for the Treatment of Psychiatric Disorders

A growing body of in vitro and in vivo evidence has demonstrated that trace amine-associated receptor 1 (TAAR1) could negatively...

One Stop Target-to-Hit Platform: STATs

STAT proteins are key mediators of cellular immunity, proliferation, apoptosis, and differentiation. STATs are known to play a role in...

OncoWuXi Express: Review of SITC 2023 Annual Meeting

Review of SITC 2023 Annual Meeting The 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) was held...

Preclinical platform for nucleic acid drug evaluation: siRNA and mRNA therapeutics

SITC Poster #59: Since the emergence of the COVID-19 pandemic, numerous nucleic-acid therapeutics have been approved for clinical use. Distinguished...

Baricitinib treatment reduces the expansion of CD8+ T cells in C3H mice with skin grafts-induced...

SITC Poster #452: Alopecia areata (AA) is an autoimmune disease characterized by patchy and sudden hair loss without scarring, resulting...

Administration of JAK and TYK2 inhibitors successfully ameliorate the severity of T cell transfer-induced colitis...

SITC Poster #446: Inflammatory bowel disease (IBD) is recognized as an autoimmune disorder characterized by chronic inflammation of the digestive...

Upregulation of drug metabolism enzymes mediates ADC resistance in a HER2-positive cancer cell line

SITC Poster #1162: Enhertu is currently approved for the treatment of patients with HER2-positive breast cancer, gastric cancer, or HER2-mutant...

Knowledge Library